<DOC>
	<DOCNO>NCT00879983</DOCNO>
	<brief_summary>The purpose study estimate pharmacokinetics evaluate safety follow single dose azithromycin 2g extended-release powder oral suspension 3-day dose regimen azithromycin 500mg tablet Chinese healthy male subject . This study data use support azithromycin NDA China .</brief_summary>
	<brief_title>An Open Label , Randomized , Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Healthy volunteer . Male . 1845 year old . BMI 17.530.5 kg/m2 . Alcohol , drug , smoke user . Sensitive macrolide antibiotic class drug , parn heparininduced thrombocytopenia . Severe medical psychiatric condition laboratory abnormality . Blood donation . 12ECG abnormal . Treatment study drug ; clinically significant .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>azithromycin , pharmacokinetics</keyword>
</DOC>